- Home
- UFCS vs MLYS Comparison
UFCS vs MLYS Comparison
Compare UFCS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- MLYS
- Stock Information
- Founded
- UFCS 1946
- MLYS 2019
- Country
- UFCS United States
- MLYS United States
- Employees
- UFCS N/A
- MLYS N/A
- Industry
- UFCS Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- MLYS Health Care
- Exchange
- UFCS Nasdaq
- MLYS Nasdaq
- Market Cap
- UFCS 666.1M
- MLYS 1.0B
- IPO Year
- UFCS N/A
- MLYS 2023
- Fundamental
- Price
- UFCS $27.12
- MLYS $14.80
- Analyst Decision
- UFCS Buy
- MLYS Strong Buy
- Analyst Count
- UFCS 2
- MLYS 4
- Target Price
- UFCS $30.00
- MLYS $27.00
- AVG Volume (30 Days)
- UFCS 133.8K
- MLYS 922.1K
- Earning Date
- UFCS 08-05-2025
- MLYS 08-12-2025
- Dividend Yield
- UFCS 2.33%
- MLYS N/A
- EPS Growth
- UFCS N/A
- MLYS N/A
- EPS
- UFCS 2.54
- MLYS N/A
- Revenue
- UFCS $1,288,423,000.00
- MLYS N/A
- Revenue This Year
- UFCS $11.31
- MLYS N/A
- Revenue Next Year
- UFCS $10.61
- MLYS N/A
- P/E Ratio
- UFCS $10.68
- MLYS N/A
- Revenue Growth
- UFCS 14.59
- MLYS N/A
- 52 Week Low
- UFCS $18.04
- MLYS $8.24
- 52 Week High
- UFCS $31.70
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- UFCS 38.82
- MLYS 53.41
- Support Level
- UFCS $27.46
- MLYS $13.44
- Resistance Level
- UFCS $28.35
- MLYS $14.70
- Average True Range (ATR)
- UFCS 0.65
- MLYS 0.67
- MACD
- UFCS -0.13
- MLYS 0.12
- Stochastic Oscillator
- UFCS 8.17
- MLYS 99.44
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.